Human papillomavirus genotypes in asymptomatic young women from public schools in Rio de Janeiro, Brazil;Genótipos de papilomavírus humanos em mulheres jovens assintomáticas de escolas públicas do Rio de Janeiro, Brasil

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 43, Issue 1, 2010, Pages 4-8

  Oliveira, Ledy Horto Santos ^a   Ferreira, Maria Diva Paes Lima ^a   Augusto, Everton Faccini ^a   Melgaço, Fabiana Gil ^a   Santos, Larissa Silva ^a   Cavalcanti, Silvia Maria Baeta ^a   Rosa, Maria Luiza Garcia ^a  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Cohort study; Genotypes; Human papillomavirus; Restriction fragment length polymorphism; Young women

Indexed keywords

DNA;

ADOLESCENT; ADULT; ARTICLE; BRAZIL; CONDOM; DEMOGRAPHY; FEMALE; GENE AMPLIFICATION; GENOTYPE; GROUPS BY AGE; GYNECOLOGICAL EXAMINATION; HEALTH PROMOTION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; LIFESTYLE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCREENING; SEXUAL EDUCATION; SEXUALITY; STRUCTURED QUESTIONNAIRE; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE; VIRUS TYPING; WART VIRUS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 77950949256     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0037-86822010000100002     Document Type: Article

References (29)

1. Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 31:3-13.
2. Widdice LE, Moscicki AB. Updated guidelines for papanicolaou tests, colposcopy, and human papillomavirus testing in adolescents. J Adolesc Health 2008; 43: S41-51.
3. Paiva V, Calazans G, Venturi G, Dias R. [Age and condom use at first sexual intercourse of Brazilian adolescents. Rev Saude Publica 2008; 42(suppl 1): 45-53.
4. Lenselink CH, Melchers WJ, Quint WG, Hoebers AM, Hendriks JC, Massuger LF, et al. Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands. PLoS ONE 2008; 3: e3743.
5. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157: 218-226.
6. Naud P, Matos J, Hammes L, Stuckzynski J, Brouwers K, Magno V, et al. Factors predicting intermediate endpoints of cervical cancer and exposure to human papillomavirus (HPV) infections in young women screened as potential targets for prophylactic HPV vaccination in south of Brazil. Eur J Obstet Gynecol Reprod Biol 2006; 124: 110-118.
7. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324: 17-27.
8. Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, Delius H, et al. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis 1994; 170: 1077-1085.
9. Viscidi RP, Schiffman M, Hildesheim A, Herrero R, Castle PE, Bratti MC, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004; 13: 324-327.
10. Ault KA. Long-term efficacy of human papillomavirus vaccination. Gynecol Oncol 107: S27-30, 2007.
11. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-2119.
12. Manos MM, Ting T, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. The use of polymerase chain reaction amplification for the detection of genital human papillomavirus. Cancer Cells 1989; 7: 209-214.
13. Gall K PD, Pavelic J, Audy-Jurkovic S, Pavelic K. PCR amplification of DNA from stained cytological smears. Journal of Clinical Pathlology 1993; 46: 378-379.
14. Ralston Howe ELZ, McGlennen RC, Hellerstedt WL, Downs Jr LS. Type-specific prevalence and persistence of human papillomavirus in women in the United States who are referred for typing as a component of cervical cancer screening. Am J Obstet Gynecol 2009; 200: 245.e1-.e7.
15. Castle PE, Jeronimo J, Schiffman M, Herrero R, Rodriguez AC, Bratti MC, et al. Age-related changes of the cervix influence human papillomavirus type distribution. Cancer Res 2006; 66: 1218-1224.
16. Mount SL, Papillo JL. A study of 10,296 pediatric and adolescent Papanicolaou smear diagnoses in northern New England. Pediatrics 1999; 103: 539-545.
17. Woodman CB, Collins S, Rollason TP, Winter H, Bailey A, Yates M, et al. Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia. Lancet 2003; 361: 40-43.
18. Spinillo A, Dal Bello B, Alberizzi P, Cesari S, Gardella B, Roccio M, et al. Clustering patterns of human papillomavirus genotypes in multiple infections. Virus Res 2009; 142: 154-159.
19. Zuna RE, Allen RA, Moore WE, Lu Y, Mattu R, Dunn ST. Distribution of HPV genotypes in 282 women with cervical lesions: evidence for three categories of intraepithelial lesions based on morphology and HPV type. Mod Pathol 2007; 20: 167-174.
20. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527.
21. Meyer T, Arndt R, Beckmann ER, Padberg B, Christophers E, Stockfleth E. Distribution of HPV 53, HPV 73 and CP8304 in genital epithelial lesions with different grades of dysplasia. Int J Gynecol Cancer 2001; 11: 198-204.
22. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366: 991-998.
23. Menzo S, Ciavattini A, Bagnarelli P, Marinelli K, Sisti S, Clementi M. Molecular epidemiology and pathogenic potential of underdiagnosed human papillomavirus types. BMC Microbiol 2008; 8: 112.
24. Molano M, Posso H, Weiderpass E, van den Brule AJ, Ronderos M, Franceschi S, et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer 2002; 87: 324-333.
25. Gargiulo F, De Francesco MA, Schreiber C, Ciravolo G, Salinaro F, Valloncini B, et al. Prevalence and distribution of single and multiple HPV infections in cytologically abnormal cervical samples from Italian women. Virus Res 2007; 125: 176-182.
26. Ault KA. Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecol Oncol 2007; 107: S31-33.
27. Stanley M, Gissmann L, Nardelli-Haefliger D. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. Vaccine 2008; 26 (suppl 10: K62-67.
28. Murta EFC. Vacina contra o HPV ou contra o câncer de colo uterino? Revista Brasileira de Ginecologia e Obstetrícia 2007; 29: 548-548.
29. Bosch FX, Castellsague X, de Sanjose S. HPV and cervical cancer: screening or vaccination? Br J Cancer 2008; 98: 15-21.